← Back to Clinical Research · Sponsor: Eli Lilly · Duration: up to 42 weeks · ClinicalTrials.gov: NCT06345066
Currently Recruiting · Clinical Research
Eloralintide + Tirzepatide in Overweight & Obesity
A study of LY3841136 (eloralintide), a GIP receptor agonist, given together with tirzepatide in adults who are overweight or have obesity.
About This Study
What is being studied?
This study evaluates LY3841136 (eloralintide) — an investigational GIP receptor agonist — given in combination with tirzepatide in adults who are overweight or living with obesity. The primary focus is safety and tolerability, with body-weight change and the drug’s pharmacokinetics assessed as secondary measures.
Why combine these agents?
Tirzepatide is already a dual GIP/GLP-1 receptor agonist. Adding eloralintide is intended to explore whether further engaging the GIP pathway can enhance weight-management outcomes. Because this is an early-phase study, careful safety monitoring is central to the design.
Eligibility Criteria
Who can participate?
Eligibility is confirmed at a screening visit. The summary below covers the main criteria; our research team reviews the full list with you.
Key Inclusion Criteria
• Adults age 18–65 years
• BMI 27–45 kg/m² (overweight or obese)
• Otherwise generally healthy
• Adults age 18–65 years
• BMI 27–45 kg/m² (overweight or obese)
• Otherwise generally healthy
Key Exclusion Criteria
• Type 1 or type 2 diabetes
• Clinically significant ECG abnormality
• Participation in another clinical trial within the prior 30 days
• Type 1 or type 2 diabetes
• Clinically significant ECG abnormality
• Participation in another clinical trial within the prior 30 days
What Participation Involves
What can I expect?
This is an early-phase study lasting up to 42 weeks. Participants receive tirzepatide together with the investigational agent and are followed closely with study visits that include safety assessments, body-weight measurements, and blood draws to characterize how the medication behaves in the body.
Interested?
Talk to our research team
If you are overweight or living with obesity and would like to learn whether this study is a fit, contact our research team. We will review eligibility and what participation involves with you. Email research@endotrials.org or call our office.
If you are overweight or living with obesity and would like to learn whether this study is a fit, contact our research team. We will review eligibility and what participation involves with you. Email research@endotrials.org or call our office.